scholarly journals Is fludeoxyglucose-fluorodeoxyglucose-positron emission tomography/computed tomography (18F-FDG-PET/CT) really useless in staging pulmonary carcinoid tumors and in discriminating histological subtypes? Controversial points and future perspectives

2015 ◽  
Vol 10 (3) ◽  
pp. 217 ◽  
Author(s):  
Filippo Lococo ◽  
Alessandro Stefani ◽  
Giorgio Treglia
Keyword(s):  
Emission Tomography ◽  
Fluorodeoxyglucose Positron Emission Tomography ◽  
Future Perspectives ◽  
Histological Subtypes ◽  
Pulmonary Carcinoid ◽  
Positron Emission ◽  
Pet Ct ◽  
18F Fdg ◽  
Fdg Pet Ct ◽  
Fluorodeoxyglucose Positron Emission

scholarly journals Case: Incidental 18F-fluorodeoxyglucose-positron emission tomography/computed tomography prostate uptake: How should these patients be managed?

2017 ◽  
Vol 11 (7) ◽  
pp. E318-20
Author(s):  
Anne Couture ◽  
Mounsif Azizi ◽  
Daniel Taussky ◽  
Michael McCormack
Keyword(s):  
Prostate Cancer ◽  
Fdg Pet ◽  
Screening Tool ◽  
Emission Tomography ◽  
Fluorodeoxyglucose Positron Emission Tomography ◽  
Positron Emission ◽  
Pet Ct ◽  
18F Fdg ◽  
Fdg Pet Ct ◽  
Fluorodeoxyglucose Positron Emission

18F-fluorodeoxyglucose-positron emission tomography/ computed tomography (18F-FDG PET/CT) is a widely used diagnostic tool for whole-body imaging, and incidental prostatic uptake occurs in approximately 1% of patients undergoing the exam. Is 18F-FDG PET/CT a reliable screening tool for prostate cancer? Should these patients undergo transrectal ultrasound (TRUS)-guided prostate biopsies? Studies have indicated that 18F-FDG PET/CT has a low positive predictive value for prostate cancer and is not recommended for screening;1 however, other studies suggest that when a discrete focal 18F-FDG uptake is discovered without coincidental calcification, particularly in the peripheral zone of the prostate, further clinical evaluation is recommended. We present two patients with incidental 18F-FDG PET/CT prostatic uptake who were found to have high-grade prostate cancer. Although 18F-FDG PET/CT has not been determined to be a reliable screening tool for prostate cancer, patients with incidental 18F-FDG uptake in the prostate should be referred for urological evaluation.

Sign in / Sign up

Export Citation Format

Share Document